 |
2011
Developing an international network for breast cancer research: the BIG experience |
| Clinical Investigation 1(5), 623-628, 2011 |
Correlation between docetaxel-induced skin toxicity and the use of steroids and H2 blockers: A multi-institution survey. |
| 河口浩介、石黒 洋、森田智視、中村清吾、大野真司、増田慎三、岩田広治、青儀健二郎、黒井克昌、戸井雅和； Japan Breast Cancer Research Group (JBCRG) |
| Breast Cancer Research and Treatment, 130(2) : 627-634, 2011 |
Docetaxel Followed by Fluorouracil/Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy for Patients With Primary Breast Cancer |
| 岩田広治、佐藤信昭、増田慎三、中村清吾、山本尚人、黒井克昌、黒住昌史、津田 均、秋山 太、大橋靖雄、戸井雅和 |
| Japanese Journal of Clinical Oncology 41: 867-875, 2011 |
2010
Japan Breast Cancer Research Group (JBCRG) |
| 黒井克昌、柏 喜代美、戸井雅和、中村清吾、岩田広治、大野真司、増田慎三、青儀健二郎、佐藤信昭、笹野公伸 |
| 腫瘍内科 6(4): 360-368, 2010 |
Economic evaluation of the 21-gene signature (Oncotype DX(®)) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03). |
| 近藤正英、星 淑玲、山中竹春、石黒 洋、戸井雅和 |
| Breast Cancer Res Treat. 2010 Nov 17. [Epub ahead of print] |
ALTTO試験. |
| 黒井克昌 |
| Cancer Board乳癌 1(1): 58, 2010. |
JBCRG-M02 |
| 黒井克昌 |
| Cancer Board乳癌 3(1): 91, 2010. |
JBCRG-07 |
| 増田慎三 |
| Cancer Board乳癌 3(1): 92, 2010 |
Clinical Significance of the 21-Gene Signature (Oncotype DX) in Hormone Receptor-Positive Early Stage Primary Breast Cancer in the Japanese Population |
| Toi M, Iwata H, Yamanaka T, Masuda N, Ohno S, Nakamura S, Nakayama T, Kashiwaba M, Kamigaki S, Kuroi K; and the Japan Breast Cancer Research Group-Translational Research |
| Cancer 2010, July 1: 3113-3118 |
2009
術前薬物療法の新展開―JBCRG studyのあゆみ |
| 山城大泰 戸井雅和 |
| 医学のあゆみ Vol 230, No1,p57-61, 2009 |
SUPREMO(BIG2-04)試験. |
| 黒井克昌 |
| Cancer Board乳癌 2(1): 68, 2009. |
CREATE-X (JBCRG-04) 試験. |
| 増田慎三 |
| Cancer Board乳癌 2(1) 70, 2009. |
「術前化学療法; 治療効果の評価」みんなに役立つ乳癌の基礎と臨床(戸井雅和 編集) |
| 黒井克昌 |
| 医薬ジャーナル社, p654-662, 2009 |
An overview of JBCRG activities |
| Katsumasa Kuroi, Masakazu Toi |
| BIG newsletter volume 11 number1 2009 |
Supremo trial expands into Asia |
| BIG newsletter volume 11 number2 2009 |
Japan Breast Cancer Research Group (JBCRG) |
| Katsumasa Kuroi |
| European Society of Breast Cancer Specialists – Eusoma Newsletter 2009 |
2008
原発乳癌に対するFEC followed by docetaxel 100mg/m2併用療法による術前化学療法の検討 -JBCRG02- |
| 中村 清吾、増田 慎三、岩田 広治、戸井 雅和、黒井 克昌、黒住 昌史、津田 均、秋山 太; Japan Breast Cancer Research Group (JBCRG). |
| 乳癌の臨床 23(2):111-117, 2008 |
PhaseII study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival |
| Toi M, Nakamura S, Kuroi K, Iwata H, Ohno S, Masuda N, Kusama M, YamazakiK, Hisamatsu K, Sato Y, Kashiwaba M, Kaise H, Kurosumi M, Tsuda H, Akiyama F,Ohashi Y, Takatsuka Y; for Japan Breast Cancer Research Group (JBCRG) |
| Breast Cancer Res Treat. 2008 Aug;110(3):531-9. Epub 2007 Sep 19 |
2007
乳癌周術期化学療法の現状およびSupportive Careの工夫―JBCRG01試験アンケートより― |
| 増田 慎三 、戸井 雅和、高塚 雄一 、中村 清吾 、岩田 広治、大野 真司、黒井 克昌、日馬 幹弘 、久松 和史、山崎 弘資 、辛 栄成 、佐藤 康幸 、海瀬 博史 、柏葉 匡寛 、岩瀬 弘敬 、黒住 昌史、津田 均 、秋山 太; Japan Breast Cancer Research Group (JBCRG). |
| 癌と化学療法 2007 Vol.34,No.10, Oct;1609-1615. |
JBCRG03:Docetaxel 75mg/m2 followed by FEC100 mg/m2による術前化学療法 |
| 柏葉 匡寛、若林 剛 、中村 清吾 、黒井 克昌、岩田 広治、大野 真司 、増田 慎三 、佐藤 信昭 、麻賀 太郎 、山本 尚人 、青儀 健二郎、佐藤 康幸 、黒住 昌史 、津田 均 、秋山 太 、戸井 雅和, Japan BreastCancer Research Group （JBCRG） |
| 乳癌の臨床 2007,Vol.22 No.5, p372-375 |
2006
Japan Breast Cacer Research Group (JBCRG) Trials Update. |
| Kuroi K, Toi M, Nakamura S, Iwata H, Ohno S, Takatsuka Y; Japan Breast Cancer Research Group (JBCRG). |
| BIG NEWS LETTER 2006,8 (1) |
Issues in the Assessment of the Pathologic Effect of Primary Systemic Therapy for Breast Cancer |
| Kuroi K, Toi M, Tsuda H, Kurosumi M, Akiyama F; Japan Breast Cancer Research Group (JBCRG). |
| Breast Cancer. 2005; 13(1): 38-48. |
2005
Interim analysis of a phaseII trial of cyclophosphamide, epirubicin and
5-fluorouracil (CEF) followed by |
| Iwata H, Nakamura S, Toi M, Shin E, Masuda N, Ohno S, Takatsuka Y,Hisamatsu K, Yamazaki K, Kusama M, Kaise H, Sato Y, Kuroi K, Akiyama F, Tsuda H, Kurosumi M; Japan Breast Cancer Research Group (JBCRG). |
| Breast Cancer. 2005;12(2):99-103. |
Update results of FEC followed by docetaxel neoadjuvant trials for primary breast cancer |
| Ohno S, Toi M, Kuroi K, Nakamura S, Iwata H, Kusama M, Masuda N, Yamazaki K, Hisamatsu K, Sato Y, Takatsuka Y, Shin E, Kaise H, Kurozumi M, Tsuda H, Akiyama F; Japan Breast Cancer Research Group (JBCRG). |
| Biomed Pharmacother.2005 Oct;59 Suppl 2:S323-4. |
Unargued issues on the pathological assessment of response in primary systemic therapy for breast cancer. |
| Kuroi K,. Toi M, Tsuda H, Kurosumi M, Akiyama F; Japan Breast Cancer Research Group (JBCRG). |
| Biomed Pharmacother. 2005 Oct;59 Suppl 2:S387-92. |
From the Japan Breast Cancer Research Group (JBCRG): How to define pCR: Our Challenge. |
| Kuroi K, Toi M, Tsuda H, Kurosumi M, Akiyama F; Japan Breast Cancer Research Group (JBCRG). |
| BIG NEWS LETTER 2005, 7(1), |
